Magnetic Medicine - 2/24/14
Using tiny particles designed to target cancer-fighting immune cells, Johns Hopkins researchers have trained the immune systems of mice to fight melanoma, a deadly skin cancer.
Publication date: Available online 21 August 2019Source: Seminars in Cancer BiologyAuthor(s): Francesco Spagnolo, Andrea Boutros, Enrica Tanda, Paola QueiroloAbstractThe past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large...
AbstractImmunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-based immunotherapy has limitations. Many tumors, such as pancreatic cancer, are less responsive to checkpoint inhibitors, where patients tend to have a limited duration of benefit and where clinical responses are more robust in patients who are positive for predictive biomarkers. One of the critical factors that influence the efficacy of immunotherapy is the tumor microenvironment (TME), which contains a hete...
ConclusionsMEDI0680 induced peripheral T-cell proliferation and increased plasma IFN γ and associated chemokines regardless of clinical response. CD8+ T-cell tumor infiltration and tumoral gene expression ofIFNG, CD8A,CXCL9, and granzyme K (GZMK) were also increased following MEDI0680 administration.Trial registrationNCT02013804; date of registration December 12, 2013.
Blood vessels deliver oxygen and nutrients to every part of the body, remove waste and provide gateways for immune cells and other cells (pericytes, smooth muscle cells) that form part of these vessels around the principal endothelial cells. Vasculogenic mimicry (VM) is a tumor blood supply system that occurs independently of angiogenesis or endothelial cells, and is associated with poor survival in cancer patients. Aberrant expression of VE-cadherin has been strongly associated with VM. Even more, human malignant melanoma cells have a constitutively high expression of phospho-VEC (pVEC) at Y658. In this review we focus on...
We report the estimation of the percentage of stroma (POS) using digital pathology in a large population-ascertained cohort of primary melanomas. Consent was obtained from participants in the Leeds Melanoma Cohort Study to access and sample tumor FFPE blocks. H&E-stained slides were digitally scanned and blocks were sampled for gene expression studies using a tissue microarray needle; this yielded a core of tissue from which RNA was extracted and assayed using Illumina WGDASL.
Importance: Melanoma is a highly aggressive cancer with extremely poor late stage survival. Those with a previous melanoma diagnosis have a 9-fold increased risk for developing a second primary melanoma compared with the general population. Yet, guidelines for dermatologic follow-up full body skin examinations (FBSEs) after diagnosis of stage I melanoma are ill-defined and vary widely.
Introduction: The incidence of both melanoma and nonmelanoma skin cancer is increasing at an alarming rate, particularly for minority populations. Outcomes are often worse in these populations due to delayed detection and treatment, attributed to barriers such as decreased understanding about skin cancers and limited access to dermatological care from lack of insurance. Uninsured patients make up a smaller fraction of dermatology practices than would be predicted by their prevalence in the population.
Background: The incidence of melanoma and nonmelanoma skin cancer has been increasing in all age groups including children and adolescents. Prior studies in the pediatric population have shown low rates of sun protection behaviors and only modest improvement over the past several decades.
This study aimed to compare the quality of life (QoL) of patients with BCC against that of patients with relapse-free MM.
Background: Immune checkpoint inhibitors (ICI) such as anti-programmed death protein 1 (anti-PD-1) antibodies produce durable responses in a subset of cancer patients. ICI can produce immune-related adverse events (irAEs). Among the earliest and most common irAEs are skin toxicities. Several studies have associated the development of irAEs with increased treatment efficacy, though it remains unclear whether steroid treatment for irAEs interferes with the antitumor effects of ICI. We sought to evaluate the effect of cutaneous irAEs on treatment outcomes.